Johnson & Johnson Gain FDA Approval For New Booster Shot That Is 79% More Effective at Causing Blood Clots
Johnson & Johnson (NYSE:JNJ) is yet again making headlines after the pharmaceutical company was granted FDA approval for their new booster shot.
Get Our Activist Investing Case Study!
Get the entire 10-part series on our in-depth study on activist investing in PDF. Save it to your desktop, read it on your tablet, or print it out to read anywhere! Sign up below!
Q3 2021 hedge fund letters, conferences and more
Disclaimer: This is a satirical article.
Johnson & Johnson Shares Soar On Its Booster Shot News
Johnson & Johnson boasted about its lack of safety, citing “We out did ourselves with this one. Our new booster shot is now 79% more likely to cause blood clots, as to our previous jab which only had a roughly 32.5% chance at giving one a blood clot.”
Johnson & Johnson shares soared on the good news.
This post first appeared on The Stonk Market
Disclaimer: This is a satirical article.
Updated on Oct 6, 2021, 1:21 pm
Source valuewalk